Moleculin Biotech, Inc. (MBRX) Stock

Moleculin Biotech, Inc. (MBRX) is a Healthcare stock trading at $0.59 (as of 2026-08-21), with a market capitalization of $11.50M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing drug candidates for highly resistant tumors and viruses. Its pipeline includes Annamycin, WP1066, WP1220, and WP1122, which are in various clinical stages for conditions such as relapsed or refractory AML, brain and other cancers, cutaneous T-cell lymphoma, and COVID-19, with collaborations involving MD Anderson and other partners.

Valuation — source: SEC EDGAR (first-party)

Price	$0.59
Market Cap	$11.50M
Price / Book	0.99
FCF Yield	-151.0%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)

$0.00

Financial Health — source: SEC EDGAR

Altman Z-Score

-16.36 (distress)

Valuation vs Sector & Industry

Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	SABBY MANAGEMENT, LLC ($171798.00)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Walter V. Klemp
Employees	17
Country	US
IPO Date	2016-06-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• BioVie Inc. (BIVI)
• Phio Pharmaceuticals Corp. (PHIO)
• Kiora Pharmaceuticals, Inc. (KPRX)
• Aspire Biopharma Holdings, Inc. (ASBP)
• Bullfrog AI Holdings, Inc. Common Stock (BFRG)
• Theriva Biologics, Inc. (TOVX)
• MetaVia Inc. (MTVA)
• Imunon, Inc. (IMNN)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.